Table 2.
Nanoformulations studied for the treatment of fungal infections caused by the Aspergillus sp..
| Nanoparticle | Drug (*) | Fungi | In vitro/in vivo | References |
|---|---|---|---|---|
| PLGAvv | AmB | A. fumigatus | In vivo (mice) | Italia et al., 2011; Van de Ven et al., 2012 |
| VOR | In vivo (rabbits) | Yang et al., 2011 | ||
| Chitosan biguanidine | Silver |
A. fumigatus
G. candidum S. recemosum |
In vitro | Salama et al., 2016 |
| PMA | AmB | A. fumigatus | In vitro/in vivo (mice) | Shirkhani et al., 2015 |
| PEG/PLA | ITZ |
A. fumigatus
C. albicans |
In vitro | Essa et al., 2013 |
| PEG-LNPs | AmB | In vitro/in vivo (rats and mice) | Jung et al., 2009 | |
| Alginate oligosaccharides (OligoG) | – |
C. albicans
C. parapsilosis C. Krusei C. lusitaniae C. tropicalis C. glabrata niger A. fumigatus A. flavus |
In vitro | Tøndervik et al., 2014 |
| mPEG-b-P-(Glu-co-Phe)) | AmB | A. fumigatus | in vivo (mice) | Yang et al., 2018 |
| Nanossuspension | AmB |
C. albicans
A. fumigatus T. rubrum |
In vitro/in vivo (mice) | Van de Ven et al., 2012 |
| ITZ | A. fumigatus | In vivo (quails) | Wlaz et al., 2015 | |
| Liposomal (AmBisome®) | AmB | A. fumigatus | In vivo (mice) | Clemons et al., 2005; Olson et al., 2006, 2010, 2015; Lewis et al., 2007; Jung et al., 2009; Italia et al., 2011; Seyedmousavi et al., 2013; Siopi et al., 2019 |
| In vivo (rabbits and mice) | Sheikh et al., 2010. | |||
| In vivo (human) | Newton et al., 2016; Godet et al., 2017 | |||
| Lipossomal | AmB | A. fumigatus | In vitro/in vivo (guinea pig) | Zhao et al., 2015 |
| Liposomal—Lambin® (Lbn) | AmB | A. fumigatus | In vivo (mice) | Olson et al., 2015 |
| Lipossomal (Abelcet®) | AmB | A. fumigatus | In vivo (mice) | Olson et al., 2006; Lewis et al., 2007 |
| In vivo (rats) | Cicogna et al., 1997 | |||
| SLNs | NAT | A. fumigatus and C. albicans | In vitro/ex vivo (goat corneas) | Khames et al., 2019 |
(*)
Drugs: AmB, Amphotericin B; VOR, voriconazole; ITZ, Itraconazole; NYS, Nystatin.